Literature DB >> 9703483

Clinical pharmacology and toxicology of dichloroacetate.

P W Stacpoole1, G N Henderson, Z Yan, M O James.   

Abstract

Dichloroacetate (DCA) is a xenobiotic of interest to both environmental toxicologists and clinicians. The chemical is a product of water chlorination and of the metabolism of various drugs and industrial chemicals. Its accumulation in groundwater and at certain Superfund sites is considered a potential health hazard. However, concern about DCA toxicity is predicated mainly on data obtained in inbred rodent strains administered DCA at doses thousands of times higher than those to which humans are usually exposed. In these animals, chronic administration of DCA induces hepatotoxicity and neoplasia. Ironically, the DCA doses used in animal toxicology experiments are very similar to those used clinically for the chronic or acute treatment of several acquired or hereditary metabolic or cardiovascular diseases. As a medicinal, DCA is generally well tolerated and stimulates the activity of the mitochondrial pyruvate dehydrogenase enzyme complex, resulting in increased oxidation of glucose and lactate and an amelioration of lactic acidosis. By this mechanism, the drug may also enhance cellular energy metabolism. DCA is dehalogenated in vivo to monochloroacetate and glyoxylate, from which it can be further catabolized to glycolate, glycine, oxalate, and carbon dioxide. It remains to be determined whether important differences in its metabolism and toxicology exist in humans between environmentally and clinically relevant doses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703483      PMCID: PMC1533324          DOI: 10.1289/ehp.98106s4989

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  11 in total

Review 1.  Chlorination of drinking water and cancer: a review.

Authors:  F H Mughal
Journal:  J Environ Pathol Toxicol Oncol       Date:  1992 Sep-Oct       Impact factor: 3.567

2.  Kinetics and metabolism of chloral hydrate in children: identification of dichloroacetate as a metabolite.

Authors:  G N Henderson; Z Yan; M O James; N Davydova; P W Stacpoole
Journal:  Biochem Biophys Res Commun       Date:  1997-06-27       Impact factor: 3.575

3.  Treatment of congenital lactic acidosis with dichloroacetate.

Authors:  P W Stacpoole; C L Barnes; M D Hurbanis; S L Cannon; D S Kerr
Journal:  Arch Dis Child       Date:  1997-12       Impact factor: 3.791

4.  Cyclosporine dosage can be reduced when used in combination with an anti-intercellular adhesion molecule-1 monoclonal antibody in rats undergoing heterotopic heart transplantation.

Authors:  P C Harrison; E Mainolfi; J B Madwed
Journal:  J Heart Lung Transplant       Date:  1998-02       Impact factor: 10.247

5.  Dichloroacetate as metabolic therapy for myocardial ischemia and failure.

Authors:  R M Bersin; P W Stacpoole
Journal:  Am Heart J       Date:  1997-11       Impact factor: 4.749

Review 6.  The pharmacology of dichloroacetate.

Authors:  P W Stacpoole
Journal:  Metabolism       Date:  1989-11       Impact factor: 8.694

7.  Metabolic effects of dichloroacetate in patients with diabetes mellitus and hyperlipoproteinemia.

Authors:  P W Stacpoole; G W Moore; D M Kornhauser
Journal:  N Engl J Med       Date:  1978-03-09       Impact factor: 91.245

8.  Treatment of lactic acidosis with dichloroacetate.

Authors:  P W Stacpoole; E M Harman; S H Curry; T G Baumgartner; R I Misbin
Journal:  N Engl J Med       Date:  1983-08-18       Impact factor: 91.245

9.  Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses.

Authors:  S H Curry; A Lorenz; P I Chu; M Limacher; P W Stacpoole
Journal:  Biopharm Drug Dispos       Date:  1991-07       Impact factor: 1.627

10.  Plasma concentrations and metabolic effects of intravenous sodium dichloroacetate.

Authors:  S H Curry; P I Chu; T G Baumgartner; P W Stacpoole
Journal:  Clin Pharmacol Ther       Date:  1985-01       Impact factor: 6.875

View more
  44 in total

1.  Age-Related Changes in Expression and Activity of Human Hepatic Mitochondrial Glutathione Transferase Zeta1.

Authors:  Guo Zhong; Margaret O James; Marci G Smeltz; Stephan C Jahn; Taimour Langaee; Pippa Simpson; Peter W Stacpoole
Journal:  Drug Metab Dispos       Date:  2018-05-31       Impact factor: 3.922

Review 2.  Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1.

Authors:  Margaret O James; Stephan C Jahn; Guo Zhong; Marci G Smeltz; Zhiwei Hu; Peter W Stacpoole
Journal:  Pharmacol Ther       Date:  2016-10-19       Impact factor: 12.310

Review 3.  The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options.

Authors:  Fernando Scaglia; Jennifer L Northrop
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Use of oral dichloroacetate for palliation of leg pain arising from metastatic poorly differentiated carcinoma: a case report.

Authors:  Akbar Khan
Journal:  J Palliat Med       Date:  2011-04-12       Impact factor: 2.947

5.  Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells.

Authors:  B M Madhok; S Yeluri; S L Perry; T A Hughes; D G Jayne
Journal:  Br J Cancer       Date:  2010-05-18       Impact factor: 7.640

6.  Non-Hodgkin's Lymphoma Reversal with Dichloroacetate.

Authors:  Dana F Flavin
Journal:  J Oncol       Date:  2010-09-16       Impact factor: 4.375

7.  The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine--both or neither?

Authors:  Peter W Stacpoole
Journal:  Environ Health Perspect       Date:  2010-10-04       Impact factor: 9.031

8.  Mice deficient in glutathione transferase zeta/maleylacetoacetate isomerase exhibit a range of pathological changes and elevated expression of alpha, mu, and pi class glutathione transferases.

Authors:  Cindy E L Lim; Klaus I Matthaei; Anneke C Blackburn; Richard P Davis; Jane E Dahlstrom; Mark E Koina; M W Anders; Philip G Board
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

9.  Clarification of the role of key active site residues of glutathione transferase zeta/maleylacetoacetate isomerase by a new spectrophotometric technique.

Authors:  Philip G Board; Matthew C Taylor; Marjorie Coggan; Michael W Parker; Hoffman B Lantum; M W Anders
Journal:  Biochem J       Date:  2003-09-15       Impact factor: 3.857

10.  Medullary thyroid carcinoma relapse reversed with dichloroacetate: A case report.

Authors:  Dana Flavin
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.